BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24265783)

  • 1. Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis.
    Hwang JA; Kim Y; Hong SH; Lee J; Cho YG; Han JY; Kim YH; Han J; Shim YM; Lee YS; Kim DH
    PLoS One; 2013; 8(11):e79634. PubMed ID: 24265783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXA11 hypermethylation is associated with progression of non-small cell lung cancer.
    Hwang JA; Lee BB; Kim Y; Park SE; Heo K; Hong SH; Kim YH; Han J; Shim YM; Lee YS; Kim DH
    Oncotarget; 2013 Dec; 4(12):2317-25. PubMed ID: 24259349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HOXA9 inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer.
    Hwang JA; Lee BB; Kim Y; Hong SH; Kim YH; Han J; Shim YM; Yoon CY; Lee YS; Kim DH
    Mol Carcinog; 2015 Jun; 54 Suppl 1():E72-80. PubMed ID: 24817037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
    Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
    PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4.
    Scherf DB; Sarkisyan N; Jacobsson H; Claus R; Bermejo JL; Peil B; Gu L; Muley T; Meister M; Dienemann H; Plass C; Risch A
    Oncogene; 2013 Jul; 32(28):3329-38. PubMed ID: 22945651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
    Tang X; Yin X; Xiang T; Li H; Li F; Chen L; Ren G
    Cancer Biomark; 2012-2013; 12(1):11-9. PubMed ID: 23321465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer.
    Liu WB; Jiang X; Han F; Li YH; Chen HQ; Liu Y; Cao J; Liu JY
    Cell Death Dis; 2013 Oct; 4(10):e882. PubMed ID: 24157876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
    Liu C; Lv D; Li M; Zhang X; Sun G; Bai Y; Chang D
    Int J Oncol; 2017 Jun; 50(6):2079-2090. PubMed ID: 28440397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
    Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells.
    Bui C; Ouzzine M; Talhaoui I; Sharp S; Prydz K; Coughtrie MW; Fournel-Gigleux S
    FASEB J; 2010 Feb; 24(2):436-50. PubMed ID: 19812376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.
    Zhang Y; Xu H; Mu J; Guo S; Ye L; Li D; Peng W; He X; Xiang T
    J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HS3ST2 modulates breast cancer cell invasiveness via MAP kinase- and Tcf4 (Tcf7l2)-dependent regulation of protease and cadherin expression.
    Vijaya Kumar A; Salem Gassar E; Spillmann D; Stock C; Sen YP; Zhang T; Van Kuppevelt TH; Hülsewig C; Koszlowski EO; Pavao MS; Ibrahim SA; Poeter M; Rescher U; Kiesel L; Koduru S; Yip GW; Götte M
    Int J Cancer; 2014 Dec; 135(11):2579-92. PubMed ID: 24752740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer.
    Yang LH; Xu HT; Li QC; Jiang GY; Zhang XP; Zhao HY; Xu K; Wang EH
    Tumour Biol; 2013 Apr; 34(2):749-57. PubMed ID: 23192643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1.
    Ye Z; Shen N; Weng Y; Li K; Hu L; Liao H; An J; Liu L; Lao S; Cai S
    Cancer Biol Ther; 2015; 16(7):1071-9. PubMed ID: 25961369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.
    Imoto I; Izumi H; Yokoi S; Hosoda H; Shibata T; Hosoda F; Ohki M; Hirohashi S; Inazawa J
    Cancer Res; 2006 May; 66(9):4617-26. PubMed ID: 16651412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
    Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant promoter methylation of hOGG1 may be associated with increased risk of non-small cell lung cancer.
    Qin H; Zhu J; Zeng Y; Du W; Shen D; Lei Z; Qian Q; Huang JA; Liu Z
    Oncotarget; 2017 Jan; 8(5):8330-8341. PubMed ID: 28039450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of Betaig-h3 gene in human cancer cells.
    Shao G; Berenguer J; Borczuk AC; Powell CA; Hei TK; Zhao Y
    Cancer Res; 2006 May; 66(9):4566-73. PubMed ID: 16651406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.
    Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):1927-46. PubMed ID: 27393180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.